



Senzime appointed to CEBR's "hotlist"

Uppsala, March 18, 2016. Senzime has been appointed one of ten leading medical technology companies by the CEBR - Council for European bioregions. The appointment is a further proof of Senzime's technologies within the important and large commercial area in measurement of glucose and lactate which is critical to quickly detect complications after operations and control for treatments.

"The appointment of the CEBR is very pleasing and yet another step towards our commercial breakthrough. We have managed to convey what we can and will do in the strong international competition. We have the building blocks in place, the timing is right and we face a market worth billions SEK. Here we will establish Senzime as a leading player and we meet a lot of interest from the doctors. In the Nordic countries alone, there is annually tens of thousands of operations conducted where our solutions can be used for post-operative monitoring," says Lena Söderström, CEO of Senzime AB.

For further information, please contact:

Lena Söderström, CEO of Senzime AB

Tel: +46 708-16 39 12, email: lena.soderstrom@senzime.com

TO THE EDITORS

About Senzime

Senzime develops patient-oriented systems enabling automated and continuous monitoring of vital substances such as glucose and lactate in blood and tissue. Based on Senzime's patented biosensor technology, the company offers complete patient monitoring systems for the health care market. Senzime's products consist of the CliniSenz Analyzer and OnZurf Probe that make it possible, among other things, to detect post-operative complications significantly earlier than by conventional methods, thus contributing to improved patient care and lower health care costs. The company's share is listed on Aktietorget, Stockholm. www.senzime.com

About the CEBR Medical Device Directory and Hotlist: The Council of European BioRegions asbl brings together over 60 SMEs from 11 clusters across Europe in a rapidly growing online directory dedicated to the development of medical devices. Launched in June 2016, the focus of the directory is on SMEs as developers of their own components or complete devices and has the aim to create a centralised hub for investors and partners to find the right SMEs for global development and distribution. The 2016 Hotlist celebrates 10 SMEs that have made substantial scientific or business progress since the directory launch in 2016. It was generated through nominations from the clusters participating in the directory. The Directory and Hotlist is sponsored in 2016 by Teijin Pharma Ltd.

Useful links:

- Medical Device Directory: <http://www.lifescience-cluster-innovations.space/european-medical-device-sme-directory/>
- Medical Device SME Hotlist: <http://www.lifescience-cluster-innovations.space/european-medical-device-sme-directory/hot-list/>
- April 11 webinar and registration: <http://www.lifescience-cluster-innovations.space/event/sme-medical-device-hotlist-showcase-webinar/>